TP53 and liver cancer: Notably, recent studies demonstrate an oncogenic function of wild-type p53 and its target gene PUMA in liver cancer progression (Kim et al., 2019), suggesting that P-TEFb inhibitors may exhibit clinical benefits in this unique context.